We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.

ESCEND Projectlogo

ESCEND in brief

ESCEND aims to shift the paradigm in Esophageal cancer early diagnosis and enhance current endoscopic performance by adding highly sensitive and quantitative fluorescence molecular endoscopy (FME) in real time. Read more...

Esophageal cancer is the 8th most commonly diagnosed type of cancer worldwide, affecting more than 450,000 people, and the 6th leading cause of cancer-related death. Incidence rates are steeply rising due to the increasing prevalence of major risk factors, including obesity, chronic gastroesophageal reflux disease, and Barret’s esophagus. Less than 20% 5-year survival rates are largely associated with the disease being detected late due to limitations in current diagnostic procedures. The current clinical-standard practice for early disease detection (i.e. surveillance endoscopy and random biopsies every 3-5 years) is sub-optimal and often misses dysplasia. Read more...

ESCEND will

  • statistically confirm previous pilot (Phase I) clinical data showing that the combination of high-definition white light endoscopy (HD-WLE) and fluorescence molecular endoscopy using labelled bevacizumab improves early Esophageal cancer detection over the current clinical standard (i.e. HD-WLE and random biopsy) and
  • validate Esophageal cancer biomarkers recently identified by genetic screening as targets for further improving Esophageal cancer detection and disease stratification over using labelled bevacizumab, based on retrospective analysis of Barret’s esophagus patient specimen. Earlier detection and better stratification can lead to more effective therapy and thus save lives and healthcare costs. Therefore, successful implementation of ESCEND could lead to an enormous socio-economic impact.
Helmholtz Zentrum München
Logo of Helmholtz Zentrum München (HMGU)
University Medical Center Groningen
Logo of University Medical Center Groningen (UMCG)
XVue Ltd.
Logo of XVue Ltd.
Results of real-time VEGFA-targeted NIR-FME

30.07.2019

Phase II early esophageal cancer detection study started

Our Phase II early esophageal cancer (EC) detection study ESCEND started, coordinated by Vasilis Ntziachristos. The study follows exciting results...

29.04.2019

ESCEND is registered at clinicaltrials.gov

A Prospective Follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-infrared Fluoresence Molecular Endoscopy Using...

14.03.2019

Start of the ESCEND website

The website of the ESCEND project was started on 14th of March, 2019.

We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.